The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Responder analysis of patient-reported outcomes measurement information system (PROMIS) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Agios; Blueprint Medicines; Daiichi Sankyo; Eisai; EMD Serono; GlaxoSmithKline; Immune Design; Janssen; Lilly; Loxo; Nanocell Therapy; Novartis; Plexxikon
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Methods of Treating Metastatic Sarcoma Using Talimogene Laherparepvec (T-Vec) and Pembrolizumab Combination Therapy- 62/671,625
 
Rebecca M Speck
Travel, Accommodations, Expenses - Daiichi Sankyo; Lilly
 
Xin Ye
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Emanuela Palmerini
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Lilly
Research Funding - Daiichi Sankyo; PharmaMar (Inst)
Travel, Accommodations, Expenses - Amgen; Lilly; Takeda
 
Silvia Stacchiotti
Honoraria - Lilly; PharmaMar; Takeda
Consulting or Advisory Role - Bayer; Epizyme; Immune Design; Lilly; MaxiVax; PharmaMar
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Jayesh Desai
Consulting or Advisory Role - Amgen; BeiGene; Bionomics; Eisai; Lilly; Novartis
Research Funding - Bionomics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)
 
Andrew J. Wagner
Honoraria - Novartis
Consulting or Advisory Role - Daiichi Sankyo; Five Prime Therapeutics; Lilly; Loxo
Research Funding - AADi (Inst); Celldex (Inst); Daiichi Sankyo (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
Thierry Alcindor
Consulting or Advisory Role - Amgen; Astellas Pharma; Eisai; Immune Design; Lilly; Novartis Canada Pharmaceuticals Inc; Shire; Taiho Pharmaceutical
Research Funding - CytRx Corporation (Inst); Eisai (Inst); EMD Serono (Inst); Epizyme (Inst); Lilly (Inst)
 
Kristen N. Ganjoo
Consulting or Advisory Role - Daiichi Sankyo; Immune Design; Janssen; Lilly; Novartis
 
Javier Martin Broto
Honoraria - Lilly; PharmaMar
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Eisai (Inst); GlaxoSmithKline; Lilly (Inst); Novartis (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Qiang Wang
Employment - Daiichi Sankyo
 
Dale Edward Shuster
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Bristol-Myers Squibb; Daiichi Sankyo; Exelis; Merck; Pfizer; Regeneron
 
Heather Gelhorn
Research Funding - Evidera
 
Hans Gelderblom
Patents, Royalties, Other Intellectual Property - Amgen, Boehringer-Ingelheim, Pfizer, Novartis, Pharmamar, Daiichi, Five Prime (Inst)
Other Relationship - Daiichi Sankyo